Show simple item record

dc.contributor.authorChalloner, BR
dc.contributor.authorvon Loga, K
dc.contributor.authorWoolston, A
dc.contributor.authorGriffiths, B
dc.contributor.authorSivamanoharan, N
dc.contributor.authorSemiannikova, M
dc.contributor.authorNewey, A
dc.contributor.authorBarber, LJ
dc.contributor.authorMansfield, D
dc.contributor.authorHewitt, LC
dc.contributor.authorSaito, Y
dc.contributor.authorDavarzani, N
dc.contributor.authorStarling, N
dc.contributor.authorMelcher, A
dc.contributor.authorGrabsch, HI
dc.contributor.authorGerlinger, M
dc.date.accessioned2020-04-02T10:39:09Z
dc.date.issued2021-01-04
dc.identifier.citationJournal of the National Cancer Institute, 2021, 113 (1), pp. 88 - 98
dc.identifier.issn0027-8874
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3571
dc.identifier.eissn1460-2105
dc.identifier.doi10.1093/jnci/djaa051
dc.description.abstractBACKGROUND: Gastric and gastro-esophageal junction cancers (GCs) frequently recur after resection, but markers to predict recurrence risk are missing. T-cell infiltrates have been validated as prognostic markers in other cancer types, but not in GC because of methodological limitations of past studies. We aimed to define and validate the prognostic role of major T-cell subtypes in GC by objective computational quantification. METHODS: Surgically resected chemotherapy-naïve GCs were split into discovery (n = 327) and validation (n = 147) cohorts. CD8 (cytotoxic), CD45RO (memory), and FOXP3 (regulatory) T-cell densities were measured through multicolor immunofluorescence and computational image analysis. Cancer-specific survival (CSS) was assessed. All statistical tests were two-sided. RESULTS: CD45RO-cell and FOXP3-cell densities statistically significantly predicted CSS in both cohorts. Stage, CD45RO-cell, and FOXP3-cell densities were independent predictors of CSS in multivariable analysis; mismatch repair (MMR) and Epstein-Barr virus (EBV) status were not statistically significant. Combining CD45RO-cell and FOXP3-cell densities into the Stomach Cancer Immune Score showed highly statistically significant (all P ≤ .002) CSS differences (0.9 years median CSS to not reached). T-cell infiltrates were highest in EBV-positive GCs and similar in MMR-deficient and MMR-proficient GCs. CONCLUSION: The validation of CD45RO-cell and FOXP3-cell densities as prognostic markers in GC may guide personalized follow-up or (neo)adjuvant treatment strategies. Only those 20% of GCs with the highest T-cell infiltrates showed particularly good CSS, suggesting that a small subgroup of GCs is highly immunogenic. The potential for T-cell densities to predict immunotherapy responses should be assessed. The association of high FOXP3-cell densities with longer CSS warrants studies into the biology of regulatory T cells in GC.
dc.formatPrint
dc.format.extent88 - 98
dc.languageeng
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS INC
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.titleComputational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes.
dc.typeJournal Article
dcterms.dateAccepted2020-04-02
rioxxterms.versionofrecord10.1093/jnci/djaa051
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0
rioxxterms.licenseref.startdate2021-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of the National Cancer Institute
pubs.issue1
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Gastrointestinal Cancers Clinical Trials/Gastrointestinal Cancers Clinical Trials (hon.)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Translational Oncogenomics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy/Translational Immunotherapy (TL)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/16/17 Starting Cohort
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.organisational-group/ICR/Students/PhD and MPhil/19/20 Starting Cohort
pubs.publication-statusPublished
pubs.volume113
pubs.embargo.termsNo embargo
icr.researchteamGastrointestinal Cancers Clinical Trials
icr.researchteamTranslational Oncogenomics
icr.researchteamTargeted Therapy
icr.researchteamTranslational Immunotherapy
dc.contributor.icrauthorChalloner, Benjamin
dc.contributor.icrauthorWoolston, Andrew
dc.contributor.icrauthorSemiannikova, Maria
dc.contributor.icrauthorNewey, Alice
dc.contributor.icrauthorMansfield, David
dc.contributor.icrauthorMelcher, Alan
dc.contributor.icrauthorGerlinger, Marco


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc/4.0